Education
About Us
Working with TipRanks
Follow Us
Schrodinger (SDGR)
NASDAQ:SDGR
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.73Last Year’s EPS
-0.76Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -8.39%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in software revenue and strategic collaborations, indicating positive operational momentum. However, the company faced challenges with increased operating losses and a decline in drug discovery revenue. While the progress in clinical programs and high customer retention are promising, financial strains and increased costs present challenges.Company Guidance
During the call, Schrödinger provided guidance for 2025, emphasizing plans to accelerate software business growth and advance drug discovery programs. The company anticipates software revenue growth between 10% and 15% and drug discovery revenue in the range of $45 million to $50 million. Hosted contracts are expected to account for a larger portion of the revenue, slightly reducing the fourth-quarter concentration. The software gross margin is projected to be 74% to 75%, down from 79.5% in 2024, due to the increased contribution from the predictive toxicology initiative. Operating expenses are anticipated to grow by less than 5% in 2025, with net cash used in operations expected to be lower than in 2024. Schrödinger's strong performance in key metrics, such as customer retention and annual contract values, underpins its optimistic outlook for the upcoming year.Record-Breaking Software Revenue Growth
Software revenue reached $180 million in 2024, representing a growth of over 13% year-over-year. Fourth quarter software revenue grew 16% to $80 million.
Successful Collaborations and Partnerships
Schrödinger established a new drug discovery collaboration and expanded a software agreement with Novartis. The company also expanded existing partnerships with Otsuka and Lilly.
Clinical Program Advancements
Progress in clinical programs, including the initiation of a Phase 1 study for SGR-3515 and anticipated clinical data releases for SGR-1505, SGR-2921, and SGR-3515 in 2025.
High Customer Retention
100% customer retention for those with annual contract value (ACV) of at least $500,000, and significant growth in customers with ACV over $5 million.
---
SDGR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SDGR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $21.70 | $22.25 | +2.53% |
| Nov 12, 2024 | $19.54 | $22.25 | +13.87% |
| Jul 31, 2024 | $22.28 | $22.60 | +1.44% |
| May 01, 2024 | $25.26 | $23.19 | -8.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Schrodinger (SDGR) report earnings?
Schrodinger (SDGR) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Schrodinger (SDGR) earnings time?
Schrodinger (SDGR) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SDGR EPS forecast?
SDGR EPS forecast for the fiscal quarter 2025 (Q1) is -0.73.
---
